CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NPS Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NPS Pharmaceuticals, Inc.
550 Hills Drive
Suite 310
Phone: (908) 450-5300p:908 450-5300 Bedminster, NJ  07921-1537  United States Ticker: NPSPNPSP
This company ceased filing statements with the SEC on 3/5/2015.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company’s second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). As of 1/7/2019, the Company is part of Shire PLC, which is owned by Takeda Pharmaceutical Company Limited.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201412/31/2014YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Peter G.Tombros 71 1/30/2008 9/1/1998
President, Chief Executive Officer, Director FrancoisNader 57 3/17/2008 6/1/2006
Chief Financial Officer, Executive Vice President Luke M.Beshar 55 1/1/2011 11/20/2007
11 additional Officers and Directors records available in full report.

Business Names
Business Name
Cinacalcet Royalty Sub LLC
NPS Holdings Company
NPS Pharma Argentina S.R.L.
15 additional Business Names available in full report.

General Information
Number of Employees: 365 (As of 2/11/2015)
Outstanding Shares: 108,581,155 (As of 2/11/2015)
Shareholders: 102
Stock Exchange: NASD
Federal Tax Id: 870439579
Fax Number: (302) 655-5049
Email Address: investor@npsp.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023